This forum article examines the current preclinical and clinical evidence for NAD+ augmentation as a strategy to counter brain aging and neurodegeneration, addressing key challenges such as measurement validity, brain delivery, optimal dosing, and trial design.
Restoring NAD+ to physiological levels shows promise for countering brain aging and neurodegeneration, with support from preclinical data and growing clinical evidence, though no specific efficacy numbers are reported in the abstract.
The abstract does not report primary clinical trial data; key unresolved challenges include measurement validity of brain NAD+ levels, uncertain brain delivery of NAD+ precursors, and lack of consensus on optimal dosing and trial design.
NAD+ augmentation strategies for brain aging are not yet ready for routine clinical use; clinicians should await rigorous trials that resolve delivery, dosing, and measurement questions before adopting these approaches.
